Loading…

The current diagnosis and treatment of patients with aortic valve stenosis

Aortic valve stenosis (AS) is the third most frequent cardiovascular abnormality after coronary artery disease and hypertension. A bicuspid aortic valve is the most common cause for AS until seventh decade and calcific valve degeneration is responsible thereafter. In symptomatic patients, The risk o...

Full description

Saved in:
Bibliographic Details
Published in:Future cardiology 2021-09, Vol.17 (6), p.1143-1160
Main Author: Henning, Robert J
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c299t-6728596b0a7d0868568cddb64364dd93155082009ace45787ba3f63534c02e0e3
container_end_page 1160
container_issue 6
container_start_page 1143
container_title Future cardiology
container_volume 17
creator Henning, Robert J
description Aortic valve stenosis (AS) is the third most frequent cardiovascular abnormality after coronary artery disease and hypertension. A bicuspid aortic valve is the most common cause for AS until seventh decade and calcific valve degeneration is responsible thereafter. In symptomatic patients, The risk of death increases from ≤1%/year to 2%/month. An echo valve area ≤1 cm , peak transaortic velocity ≥4 m/s, mean valve gradient ≥40 mmHg and/or computerized tomography valve calcium score >2000 Agatston units (AU) for males or more than 1200 AU for females indicate severe AS. AS stages and management are discussed. Valve replacement is based on surgical risk, valve durability/hemodynamics, need for anticoagulation and patient preferences. EuroSCORE ≥20%, Society of Thoracic Surgeons Predicted Risk of Mortality ≥8% and co-morbidities indicate high surgical risk. Surgery is recommended for low-intermediate risk patients. Transcatheter aortic valve implantation is an alternative in older patients at low, intermediate, high or prohibitive risk. Transaortic valve implantation/replacement trials are summarized. The aortic valve is one of the four valves within the heart. Aortic valve stenosis is a problem that can occur in middle age and elderly people and limits the amount of oxygen-rich blood that can be pumped by the heart to the tissues of the body. Aortic valve stenosis can cause symptoms such as shortness of breath, chest discomfort, dizziness, fainting and difficulty exercising. Treatment consists of replacement of the aortic valve with a mechanical, pig or cow valve during open heart surgery. Alternatively, a catheter (tube) with a tissue valve can be passed through a peripheral artery into the heart for placement of a new aortic valve. The catheter valve replacement option has significantly reduced the side effects and death rate of patients who undergo aortic valve replacement for aortic valve stenosis.
doi_str_mv 10.2217/fca-2020-0140
format article
fullrecord <record><control><sourceid>futurescience_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2217_fca_2020_0140</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_2217_fca_2020_0140</sourcerecordid><originalsourceid>FETCH-LOGICAL-c299t-6728596b0a7d0868568cddb64364dd93155082009ace45787ba3f63534c02e0e3</originalsourceid><addsrcrecordid>eNp1kDtPAzEQhC0EEiFQ0vsPGNaP86NEEU9Fogn1ybH3iFFyF9kOiH_PHaGl2tnVzErzEXLN4UYIbm674JkAAQy4ghMy40YpZoWzp6NWxjGtjT0nF6V8AEjjuJuRl9UGaTjkjH2lMfn3fiipUN9HWjP6upvuQ0f3vqZRFvqV6ob6IdcU6KfffiItFX9Dl-Ss89uCV39zTt4e7leLJ7Z8fXxe3C1ZEM5Vpo2wjdNr8CaC1bbRNsS41kpqFaOTvGnACgDnA6rGWLP2stOykSqAQEA5J-z4N-ShlIxdu89p5_N3y6GdQLQjiHYC0U4gRr87-rtDPWQsYSwSsD1uO4wppB7_yf4Ay3dkeQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The current diagnosis and treatment of patients with aortic valve stenosis</title><source>PubMed Central</source><creator>Henning, Robert J</creator><creatorcontrib>Henning, Robert J</creatorcontrib><description>Aortic valve stenosis (AS) is the third most frequent cardiovascular abnormality after coronary artery disease and hypertension. A bicuspid aortic valve is the most common cause for AS until seventh decade and calcific valve degeneration is responsible thereafter. In symptomatic patients, The risk of death increases from ≤1%/year to 2%/month. An echo valve area ≤1 cm , peak transaortic velocity ≥4 m/s, mean valve gradient ≥40 mmHg and/or computerized tomography valve calcium score &gt;2000 Agatston units (AU) for males or more than 1200 AU for females indicate severe AS. AS stages and management are discussed. Valve replacement is based on surgical risk, valve durability/hemodynamics, need for anticoagulation and patient preferences. EuroSCORE ≥20%, Society of Thoracic Surgeons Predicted Risk of Mortality ≥8% and co-morbidities indicate high surgical risk. Surgery is recommended for low-intermediate risk patients. Transcatheter aortic valve implantation is an alternative in older patients at low, intermediate, high or prohibitive risk. Transaortic valve implantation/replacement trials are summarized. The aortic valve is one of the four valves within the heart. Aortic valve stenosis is a problem that can occur in middle age and elderly people and limits the amount of oxygen-rich blood that can be pumped by the heart to the tissues of the body. Aortic valve stenosis can cause symptoms such as shortness of breath, chest discomfort, dizziness, fainting and difficulty exercising. Treatment consists of replacement of the aortic valve with a mechanical, pig or cow valve during open heart surgery. Alternatively, a catheter (tube) with a tissue valve can be passed through a peripheral artery into the heart for placement of a new aortic valve. The catheter valve replacement option has significantly reduced the side effects and death rate of patients who undergo aortic valve replacement for aortic valve stenosis.</description><identifier>ISSN: 1479-6678</identifier><identifier>EISSN: 1744-8298</identifier><identifier>DOI: 10.2217/fca-2020-0140</identifier><language>eng</language><publisher>Future Medicine Ltd</publisher><subject>aortic mean pressure gradient ; aortic stenosis management ; aortic stenosis signs ; aortic stenosis symptoms ; aortic valve area ; aortic valve calcium score ; bicuspid aortic valve ; bioprosthetic aortic tissue valves ; calcific aortic valve degeneration ; echocardiographic transaortic flow velocity ; EuroScore ; mechanical aortic valves ; rheumatic aortic stenosis ; Society Thoracic Surgery Prediction of Mortality Score ; surgical aortic valve replacement (SAVR) ; TAVI trials ; transthoracic aortic valve implantationt (TAVI)</subject><ispartof>Future cardiology, 2021-09, Vol.17 (6), p.1143-1160</ispartof><rights>2021 Future Medicine Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c299t-6728596b0a7d0868568cddb64364dd93155082009ace45787ba3f63534c02e0e3</cites><orcidid>0000-0002-6958-4847</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Henning, Robert J</creatorcontrib><title>The current diagnosis and treatment of patients with aortic valve stenosis</title><title>Future cardiology</title><description>Aortic valve stenosis (AS) is the third most frequent cardiovascular abnormality after coronary artery disease and hypertension. A bicuspid aortic valve is the most common cause for AS until seventh decade and calcific valve degeneration is responsible thereafter. In symptomatic patients, The risk of death increases from ≤1%/year to 2%/month. An echo valve area ≤1 cm , peak transaortic velocity ≥4 m/s, mean valve gradient ≥40 mmHg and/or computerized tomography valve calcium score &gt;2000 Agatston units (AU) for males or more than 1200 AU for females indicate severe AS. AS stages and management are discussed. Valve replacement is based on surgical risk, valve durability/hemodynamics, need for anticoagulation and patient preferences. EuroSCORE ≥20%, Society of Thoracic Surgeons Predicted Risk of Mortality ≥8% and co-morbidities indicate high surgical risk. Surgery is recommended for low-intermediate risk patients. Transcatheter aortic valve implantation is an alternative in older patients at low, intermediate, high or prohibitive risk. Transaortic valve implantation/replacement trials are summarized. The aortic valve is one of the four valves within the heart. Aortic valve stenosis is a problem that can occur in middle age and elderly people and limits the amount of oxygen-rich blood that can be pumped by the heart to the tissues of the body. Aortic valve stenosis can cause symptoms such as shortness of breath, chest discomfort, dizziness, fainting and difficulty exercising. Treatment consists of replacement of the aortic valve with a mechanical, pig or cow valve during open heart surgery. Alternatively, a catheter (tube) with a tissue valve can be passed through a peripheral artery into the heart for placement of a new aortic valve. The catheter valve replacement option has significantly reduced the side effects and death rate of patients who undergo aortic valve replacement for aortic valve stenosis.</description><subject>aortic mean pressure gradient</subject><subject>aortic stenosis management</subject><subject>aortic stenosis signs</subject><subject>aortic stenosis symptoms</subject><subject>aortic valve area</subject><subject>aortic valve calcium score</subject><subject>bicuspid aortic valve</subject><subject>bioprosthetic aortic tissue valves</subject><subject>calcific aortic valve degeneration</subject><subject>echocardiographic transaortic flow velocity</subject><subject>EuroScore</subject><subject>mechanical aortic valves</subject><subject>rheumatic aortic stenosis</subject><subject>Society Thoracic Surgery Prediction of Mortality Score</subject><subject>surgical aortic valve replacement (SAVR)</subject><subject>TAVI trials</subject><subject>transthoracic aortic valve implantationt (TAVI)</subject><issn>1479-6678</issn><issn>1744-8298</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kDtPAzEQhC0EEiFQ0vsPGNaP86NEEU9Fogn1ybH3iFFyF9kOiH_PHaGl2tnVzErzEXLN4UYIbm674JkAAQy4ghMy40YpZoWzp6NWxjGtjT0nF6V8AEjjuJuRl9UGaTjkjH2lMfn3fiipUN9HWjP6upvuQ0f3vqZRFvqV6ob6IdcU6KfffiItFX9Dl-Ss89uCV39zTt4e7leLJ7Z8fXxe3C1ZEM5Vpo2wjdNr8CaC1bbRNsS41kpqFaOTvGnACgDnA6rGWLP2stOykSqAQEA5J-z4N-ShlIxdu89p5_N3y6GdQLQjiHYC0U4gRr87-rtDPWQsYSwSsD1uO4wppB7_yf4Ay3dkeQ</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Henning, Robert J</creator><general>Future Medicine Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-6958-4847</orcidid></search><sort><creationdate>20210901</creationdate><title>The current diagnosis and treatment of patients with aortic valve stenosis</title><author>Henning, Robert J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c299t-6728596b0a7d0868568cddb64364dd93155082009ace45787ba3f63534c02e0e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>aortic mean pressure gradient</topic><topic>aortic stenosis management</topic><topic>aortic stenosis signs</topic><topic>aortic stenosis symptoms</topic><topic>aortic valve area</topic><topic>aortic valve calcium score</topic><topic>bicuspid aortic valve</topic><topic>bioprosthetic aortic tissue valves</topic><topic>calcific aortic valve degeneration</topic><topic>echocardiographic transaortic flow velocity</topic><topic>EuroScore</topic><topic>mechanical aortic valves</topic><topic>rheumatic aortic stenosis</topic><topic>Society Thoracic Surgery Prediction of Mortality Score</topic><topic>surgical aortic valve replacement (SAVR)</topic><topic>TAVI trials</topic><topic>transthoracic aortic valve implantationt (TAVI)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Henning, Robert J</creatorcontrib><collection>CrossRef</collection><jtitle>Future cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Henning, Robert J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The current diagnosis and treatment of patients with aortic valve stenosis</atitle><jtitle>Future cardiology</jtitle><date>2021-09-01</date><risdate>2021</risdate><volume>17</volume><issue>6</issue><spage>1143</spage><epage>1160</epage><pages>1143-1160</pages><issn>1479-6678</issn><eissn>1744-8298</eissn><abstract>Aortic valve stenosis (AS) is the third most frequent cardiovascular abnormality after coronary artery disease and hypertension. A bicuspid aortic valve is the most common cause for AS until seventh decade and calcific valve degeneration is responsible thereafter. In symptomatic patients, The risk of death increases from ≤1%/year to 2%/month. An echo valve area ≤1 cm , peak transaortic velocity ≥4 m/s, mean valve gradient ≥40 mmHg and/or computerized tomography valve calcium score &gt;2000 Agatston units (AU) for males or more than 1200 AU for females indicate severe AS. AS stages and management are discussed. Valve replacement is based on surgical risk, valve durability/hemodynamics, need for anticoagulation and patient preferences. EuroSCORE ≥20%, Society of Thoracic Surgeons Predicted Risk of Mortality ≥8% and co-morbidities indicate high surgical risk. Surgery is recommended for low-intermediate risk patients. Transcatheter aortic valve implantation is an alternative in older patients at low, intermediate, high or prohibitive risk. Transaortic valve implantation/replacement trials are summarized. The aortic valve is one of the four valves within the heart. Aortic valve stenosis is a problem that can occur in middle age and elderly people and limits the amount of oxygen-rich blood that can be pumped by the heart to the tissues of the body. Aortic valve stenosis can cause symptoms such as shortness of breath, chest discomfort, dizziness, fainting and difficulty exercising. Treatment consists of replacement of the aortic valve with a mechanical, pig or cow valve during open heart surgery. Alternatively, a catheter (tube) with a tissue valve can be passed through a peripheral artery into the heart for placement of a new aortic valve. The catheter valve replacement option has significantly reduced the side effects and death rate of patients who undergo aortic valve replacement for aortic valve stenosis.</abstract><pub>Future Medicine Ltd</pub><doi>10.2217/fca-2020-0140</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0002-6958-4847</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1479-6678
ispartof Future cardiology, 2021-09, Vol.17 (6), p.1143-1160
issn 1479-6678
1744-8298
language eng
recordid cdi_crossref_primary_10_2217_fca_2020_0140
source PubMed Central
subjects aortic mean pressure gradient
aortic stenosis management
aortic stenosis signs
aortic stenosis symptoms
aortic valve area
aortic valve calcium score
bicuspid aortic valve
bioprosthetic aortic tissue valves
calcific aortic valve degeneration
echocardiographic transaortic flow velocity
EuroScore
mechanical aortic valves
rheumatic aortic stenosis
Society Thoracic Surgery Prediction of Mortality Score
surgical aortic valve replacement (SAVR)
TAVI trials
transthoracic aortic valve implantationt (TAVI)
title The current diagnosis and treatment of patients with aortic valve stenosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T15%3A00%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-futurescience_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20current%20diagnosis%20and%20treatment%20of%20patients%20with%20aortic%20valve%20stenosis&rft.jtitle=Future%20cardiology&rft.au=Henning,%20Robert%20J&rft.date=2021-09-01&rft.volume=17&rft.issue=6&rft.spage=1143&rft.epage=1160&rft.pages=1143-1160&rft.issn=1479-6678&rft.eissn=1744-8298&rft_id=info:doi/10.2217/fca-2020-0140&rft_dat=%3Cfuturescience_cross%3E10_2217_fca_2020_0140%3C/futurescience_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c299t-6728596b0a7d0868568cddb64364dd93155082009ace45787ba3f63534c02e0e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true